Compare Medpace Holdings Inc (MEDP) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B). The key difference: Medpace Holdings Inc and iShares Broad USD Investment Grade Corporate Bond are close in size by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| MEDP | USIG | |
|---|---|---|
Market Cap | $16.82B | $17.53B |
Volume | 223,093 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $630.19 | $52.69 |
52-Week Low | $393.42 | $48.54 |
Typical Hold Time | 14 Days | 44 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
USIG trades at $48.765 with minimal daily movement (+0.17%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $49 levels while finding support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon's increased stake, indicating institutional confidence.
The bearish technical setup contrasts with institutional accumulation, creating a divergence worth monitoring. Key risks include market volatility and competitive pressures in the investment grade corporate bond ETF space. The absence of current fundamental metrics requires careful due diligence on underlying bond portfolio quality and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
